3T Biosciences is a startup biotech focusing on identification and validation of novel TCRs and the development of novel, TCR based therapeutic programs, with improved therapeutic indexes.
3T Biosciences, Inc.
linkedin_id=”https://www.linkedin.com/company/3tbiosciences” connections=”true” suffix=””]
3T Biosciences proprietary experimental and computational technology allows to identify novel T cell receptor targets as well as clinical toxicities to bring safe and effective therapies.
In Feb 2017, 3T Biosciences, raised $12 Mn in a seed funding round led by investors Sean Parker alongside fellow billionaire investor Peter Thiel.